บทบาทของยา Methotrexate ในการรักษาโรคมะเร็งทางโลหิตวิทยา

เอกสารอ้างอิง

Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145-

Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High-Dose Methotrexate.

Oncologist. 2016;21(12):1471-82.

Malaviya AN. Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic

inflammatory rheumatic diseases: a fascinating story. Int J Rheum Dis. 2016;19(9):844-51.

Maksimovic V, Pavlovic-Popovic Z, Vukmirovic S, Cvejic J, Mooranian A, Al-Salami H, et al. Molecular mechanism of action

and pharmacokinetic properties of methotrexate. Mol Biol Rep.2020;47(6):4699-708.

Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom DM, et al. Blood-brain barrier disruption and intraarterial

methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol. 2009;27(21):3503-9.

Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020;189(5):879-87.

Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, et al. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica. 2021;106(7):1932-42.

Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood. 2021;137(6):743-50.

Tse E, Zhao WL, Xiong J, Kwong YL. How we treat NK/T-cell lymphomas. J Hematol Oncol. 2022;15(1):74.

Jeong H, Cho H, Kim H, Chae H, Lee JB, Lee K, et al. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis. Blood Adv. 2021;5(8):2142-52.

Ong SY, de Mel S, Grigoropoulos NF, Chen Y, Tan YC, Tan MSY, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J. 2021;11(8):143

Bobillo S, Joffe E, Sermer D, Mondello P, Ghione P, Caron PC, et al. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Blood Cancer J. 2021;11(6):113.

Lee K, Yoon DH, Hong JY, Kim S, Kang EH, Huh J, et al. Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis. Int J Hematol. 2019;110(1):86-94.

Olek-Hrab K, Maj J, Chmielowska E, Jankowska-Konsur A, Olszewska B, Kręcisz B, et al. Methotrexate in the treatment of mycosis fungoides - a multicenter observational study in 79 patients. Eur Rev Med Pharmacol Sci. 2018;22(11):3586-94.

Liang B, Zheng Z, Shi Y, Chen J, Hu X, Qian H, et al. Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy. Onco Targets Ther. 2017;10:2305-13.

Hamilton BK. Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2018;2018(1):228-35.

Kawaguchi S, Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, et al. Risk factors for high-dose methotrexate-induced nephrotoxicity. Int J Hematol. 2021;114(1):79-84.